Expanded indication: Rybrevant (amivantamab) - 10/24

Rybrevant (amivantamab) - now indicated for previously treated locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.